Kidney Function Panel: eGFR, Creatinine, Cystatin C, and ACR Interpretation

The kidney function panel is one of the quietest tests in Australian pathology. It is bundled into almost every general blood request, bulk-billed under Medicare, and reported in a format that has barely changed in a decade: a serum creatinine, a calculated estimated glomerular filtration rate (eGFR), and a urea. For most reports, the numbers sit inside the lab's reference interval and receive no further attention.

That superficial simplicity hides a more interesting interpretive layer. Creatinine is a downstream marker influenced by muscle mass, recent meat ingestion, hydration status, and a list of drugs that block tubular secretion. The eGFR equation has changed twice in the last fifteen years, most recently to remove the race coefficient (Inker et al. 2021, NEJM). Cystatin C — a small protein freely filtered at the glomerulus and far less muscle-dependent than creatinine — is now formally recommended as a confirmatory marker in the KDIGO 2024 CKD Guideline, but remains rarely ordered in primary care. And the urine albumin-to-creatinine ratio (ACR) — the single most prognostic kidney marker available outside a renal clinic — is frequently omitted entirely.

This article walks through the components of the panel, the equations behind eGFR, the confounders that move each marker, and the difference between the population-defined CKD staging cutoffs and the functional optimal targets that some preventive-health frameworks now apply.

What Is Measured

A complete Australian kidney function workup typically contains the following components:

• Serum creatinine — a breakdown product of creatine phosphate in skeletal muscle, filtered at the glomerulus.
• Estimated glomerular filtration rate (eGFR) — a calculated value, derived from creatinine using a population equation.
• Urea (BUN) — the end-product of protein catabolism, also filtered renally but heavily influenced by protein intake and hydration.
• Cystatin C — a 13 kDa cysteine protease inhibitor produced at a relatively constant rate by all nucleated cells, used as an alternative or confirmatory filtration marker.
• Urine albumin-to-creatinine ratio (ACR) — a spot urine measurement reflecting glomerular permeability to albumin.

Sodium, potassium, chloride, and bicarbonate are often reported alongside as a urea-and-electrolytes (U&E) panel, but those are reviewed in a separate context.

How eGFR Is Calculated: CKD-EPI 2021 vs MDRD

The eGFR printed on an Australian pathology report is not a measured filtration rate. It is an estimate produced by inserting serum creatinine, age, and sex into a population-derived equation. The equation matters: the same creatinine can produce meaningfully different eGFR values depending on which formula a lab uses.

Three equations have dominated the last twenty years:

• MDRD (Modification of Diet in Renal Disease) — the original equation, validated in CKD populations and known to underestimate eGFR at higher filtration rates.
• CKD-EPI 2009 — replaced MDRD in most Australian labs from around 2012 onward, more accurate at eGFR >60 mL/min/1.73m².
• CKD-EPI 2021 (race-free) — removed the race coefficient that had previously inflated eGFR for Black patients, following recommendations from a joint NKF-ASN task force.

The CKD-EPI 2021 equation has been progressively adopted across Australian laboratories. Practically, the change shifts eGFR estimates slightly across the population — modestly lower for some, modestly higher for others — and removes a coefficient that lacked biological justification.

The result remains an estimate. eGFR is reported as a single number with implied precision, but the 95% prediction interval around any individual value is wide. A reported eGFR of 75 mL/min/1.73m² may reflect a true measured GFR anywhere from roughly 60 to 90 in the same patient on the same day.

Creatinine Confounders

Because eGFR is mathematically derived from creatinine, anything that moves creatinine independently of filtration moves the eGFR. Four confounders dominate:

Muscle mass. Creatinine production is roughly proportional to skeletal muscle mass. A heavily muscled person at 95 kg may generate substantially more creatinine per day than a sarcopenic person at 55 kg, and their eGFR will be biased downward relative to true filtration. The same equation flagging "mildly reduced kidney function" in a strength athlete may simply be measuring muscle.

Recent meat ingestion. A large cooked-meat meal — particularly slow-cooked or charred preparations — can transiently raise serum creatinine for several hours by direct ingestion of preformed creatinine. Morning fasting samples avoid this; evening or post-meal samples can be misleading.

Hydration status. Pre-renal volume depletion concentrates creatinine and lowers eGFR without any structural kidney injury. Aggressive overhydration can dilute it. The acute swings here are larger than most clinicians appreciate.

Drugs that block tubular secretion. Trimethoprim, cimetidine, and certain other agents inhibit the tubular secretion of creatinine without changing actual filtration. The result is a rise in serum creatinine and an apparent drop in eGFR — a laboratory finding rather than a renal one. Fenofibrate has a similar effect through a different mechanism.

A single creatinine, in isolation, says less than the report implies. Serial measurements at consistent hydration, fasting status, and time of day are more informative than a one-off result.

Urea (BUN): A Supporting Marker

Urea is filtered at the glomerulus and partially reabsorbed in the tubules. It rises in volume depletion, high-protein intake, gastrointestinal bleeding, and catabolic states (corticosteroids, severe illness). It falls in liver dysfunction, low-protein diets, and overhydration.

In an isolated kidney function review, urea is rarely the headline number. Its main use is in patterns: a urea-to-creatinine ratio that is disproportionately high suggests pre-renal physiology (dehydration, GI bleed, catabolism), whereas a proportional rise in both is more consistent with intrinsic kidney disease.

Cystatin C: When It Adds Value

Cystatin C is produced at a relatively stable rate by all nucleated cells, is freely filtered at the glomerulus, and is almost entirely reabsorbed and catabolised in the proximal tubule. It does not appear in urine in measurable amounts under normal conditions, and circulating levels reflect glomerular filtration far more directly than creatinine.

Its key advantage is independence from muscle mass. In populations where creatinine is unreliable as a filtration marker, cystatin C becomes the preferred input. The KDIGO 2024 guideline explicitly recommends cystatin C as a confirmatory test when creatinine-based eGFR sits in the 45–59 mL/min/1.73m² range without other evidence of kidney disease, to determine whether the value represents true CKD or simply a creatinine artefact.

Situations where cystatin C tends to outperform creatinine include:

• Athletes and individuals with high muscle mass
• Older adults with sarcopenia
• Spinal-cord injury and other states of profound muscle loss
• Chronic illness with cachexia
• Limb amputation
• Vegetarian and vegan patterns with low creatinine intake
• Borderline eGFR values where staging decisions depend on small differences

Cystatin C is not without its own confounders — thyroid dysfunction, chronic corticosteroid use, and obesity all influence circulating levels — but it is largely orthogonal to the creatinine confounders. Combined eGFR equations using both creatinine and cystatin C (eGFRcr-cys) outperform either marker alone and are the closest practical approximation to measured GFR available without isotope studies (Shlipak et al. 2013, NEJM).

In Australia, cystatin C is not bulk-billed and is typically a private-pay add-on of around $40–60. It is most useful in the borderline cases described above rather than as a routine first-line test.

Urine ACR and Microalbuminuria

The urine albumin-to-creatinine ratio is the single most prognostic kidney marker that primary care can order, and it is consistently underused. ACR reflects the integrity of the glomerular filtration barrier — its ability to retain albumin rather than allowing it to leak into the urine.

Standard cutoffs:

• Normal: ACR <3 mg/mmol
• Moderately increased albuminuria (formerly "microalbuminuria"): 3–30 mg/mmol
• Severely increased albuminuria (formerly "macroalbuminuria"): >30 mg/mmol

The clinical importance of ACR is that it adds prognostic information that eGFR alone misses. A patient with an eGFR of 75 mL/min/1.73m² and an ACR of 25 mg/mmol carries a higher risk profile than a patient with the same eGFR and an ACR of 1 mg/mmol — despite both being "normal eGFR" by conventional reporting. The KDIGO heat-map combines eGFR category and ACR category into a single risk classification precisely because the two markers are independent.

Microalbuminuria is also one of the earliest detectable changes in diabetic kidney disease and hypertensive nephropathy, often appearing years before eGFR begins to decline.

AKI vs CKD: The Time Axis

Kidney function abnormalities split into two fundamentally different categories along a time axis:

Acute kidney injury (AKI) is a rapid rise in creatinine — typically defined as a rise of 26.5 µmol/L within 48 hours, a 1.5-fold rise within 7 days, or oliguria — and is usually driven by an identifiable acute event: dehydration, sepsis, contrast exposure, nephrotoxic medication, urinary obstruction. AKI is potentially reversible.

Chronic kidney disease (CKD) is a sustained reduction in eGFR (<60 mL/min/1.73m²) or evidence of kidney damage (albuminuria, structural abnormalities, urine sediment findings) for >3 months. CKD is generally progressive, though the rate varies enormously.

The distinction matters because the interpretation of a single low eGFR is entirely different depending on which category it falls into. A one-off result without prior baseline cannot distinguish AKI from CKD — only serial measurements, the trajectory of change, and the clinical context can.

Hyperfiltration in Early Diabetes

Counterintuitively, the earliest measurable kidney abnormality in type 1 and early type 2 diabetes is not a decline in filtration but a rise. Glomerular hyperfiltration — eGFR values above the expected age-specific range, often >120 mL/min/1.73m² — reflects intraglomerular hypertension and is associated with later progression to overt diabetic kidney disease.

An eGFR of 135 in a person with longstanding poor glycaemic control is not a healthy finding. It is a marker of altered glomerular haemodynamics that, over years, contributes to nephron loss. This is why ACR is particularly important in diabetes: it can flag glomerular barrier disruption while the eGFR is still in the "supranormal" range.

For functional context on the glycaemic side of this relationship, see HbA1c optimal ranges and functional targets. For the broader vascular relationship between metabolic dysfunction and end-organ damage, including the kidney-brain axis, see metabolic dysfunction and dementia risk.

Functional Optimal Targets vs CKD Staging

Standard Australian pathology reports flag eGFR <60 mL/min/1.73m² as below the reference interval. KDIGO uses a five-tier staging system:

• G1: eGFR ≥90 (normal or high, with evidence of kidney damage)
• G2: eGFR 60–89 (mildly decreased, with evidence of kidney damage)
• G3a: eGFR 45–59 (mild to moderate decrease)
• G3b: eGFR 30–44 (moderate to severe decrease)
• G4: eGFR 15–29 (severely decreased)
• G5: eGFR <15 (kidney failure)

Albuminuria categories run in parallel: A1 (<3 mg/mmol), A2 (3–30 mg/mmol), A3 (>30 mg/mmol).

Functional and preventive-health frameworks tend to tighten the lens further. Some markers used:

• eGFR holding stable year-on-year (rate of change is more informative than absolute value)
• Urea-to-creatinine ratio within a narrow band consistent with adequate hydration
• ACR consistently <1 mg/mmol rather than simply <3 mg/mmol
• Cystatin C-based eGFR concordant with creatinine-based eGFR (no large gap suggesting muscle artefact)

These functional targets do not replace KDIGO staging. They sit alongside it as a tighter optimisation lens, particularly relevant for patients with diabetes, hypertension, gout, or a family history of CKD. Uric acid often co-travels with early kidney dysfunction; see uric acid as a metabolic marker for the related interpretation.

KDIGO 2024 Risk Classification

The KDIGO 2024 guideline reinforces the two-axis risk model that has been in place since 2012: any patient with CKD is classified by both eGFR category (G1–G5) and albuminuria category (A1–A3), and the combination defines risk. A G2 A3 patient (eGFR 60–89, ACR >30) is at substantially higher risk than a G3a A1 patient (eGFR 45–59, ACR <3) despite the latter having "worse" eGFR on paper.

The 2024 update emphasises:

• Routine ACR measurement in any patient with diabetes, hypertension, or eGFR <60
• Confirmatory cystatin C testing for borderline creatinine-based eGFR
• Identification of CKD progression rather than single-timepoint diagnosis
• Integration of cardiovascular risk assessment, given the bidirectional kidney-heart relationship

Lipid profile interpretation in CKD is its own subject, and the relationship between dyslipidaemia and renal vascular disease is well established; for the lipid framework, see the comprehensive lipid panel.

A Practical Interpretation Framework

A useful sequence for reading a kidney panel:

1. Look at the trend, not the single value. A current eGFR of 78 is interpreted very differently if the prior three results were 95, 88, and 83 versus 75, 79, and 77.
2. Account for muscle mass. In athletes or sarcopenic patients with borderline eGFR, consider cystatin C before accepting the creatinine-based result.
3. Check the ACR. Particularly in diabetes, hypertension, obesity, and any eGFR <90.
4. Review medications. Trimethoprim, cimetidine, fenofibrate, and several others can shift creatinine without changing filtration.
5. Confirm timing. Fasting morning samples avoid recent-meat artefact and reflect a more reproducible hydration state.
6. Distinguish AKI from CKD. A single abnormal result without prior context cannot be assumed to be chronic.
7. Integrate with the wider metabolic picture. Glycaemia, blood pressure, lipid profile, and uric acid all interact with renal trajectory.

Key Takeaways

• The standard Australian kidney panel reports creatinine-derived eGFR using the race-free CKD-EPI 2021 equation in most laboratories.
• Creatinine is moved by muscle mass, recent meat intake, hydration, and several common drugs — all independent of true filtration.
• Cystatin C is less muscle-dependent and is the preferred confirmatory marker in borderline creatinine-based eGFR, particularly at 45–59 mL/min/1.73m².
• Urine ACR adds independent prognostic information at any eGFR and is consistently underused in primary care.
• Hyperfiltration (eGFR above expected age range) is an early diabetes-related finding, not a sign of robust renal reserve.
• KDIGO 2024 classifies risk on a two-axis grid of eGFR category and albuminuria category, not eGFR alone.
• Functional optimal targets focus on year-on-year stability, ACR well below the 3 mg/mmol cutoff, and concordance between creatinine- and cystatin-C-based estimates rather than simply "in range".
• Trend, context, and confounder review matter more than any single number on a single report.